Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 14 articles:
HTML format
Text format



Single Articles


    March 2017
  1. GALEOTTI L, Ceccherini F, Domingo D, Laurino M, et al
    Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.
    Cancer Chemother Pharmacol. 2017 Mar 13. doi: 10.1007/s00280-017-3271.
    PubMed     Text format     Abstract available


  2. BEN HASSINE I, Gharbi H, Soltani I, Teber M, et al
    hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
    Cancer Chemother Pharmacol. 2017 Mar 12. doi: 10.1007/s00280-017-3266.
    PubMed     Text format     Abstract available


    October 2016
  3. VARATHARAJAN S, Panetta JC, Abraham A, Karathedath S, et al
    Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  4. FORSTER VJ, van Delft FW, Baird SF, Mair S, et al
    Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  5. NIELSEN SN, Grell K, Nersting J, Frandsen TL, et al
    Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  6. KIM JH, Lee C, Cheong HS, Koh Y, et al
    SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  7. OGURA M, Ishida T, Tsukasaki K, Takahashi T, et al
    Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  8. DRENBERG CD, Buaboonnam J, Orwick SJ, Hu S, et al
    Evaluation of artemisinins for the treatment of acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    November 2015
  9. FRANCIS J, Dubashi B, Sundaram R, Pradhan SC, et al
    A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  10. BRAY WM, Bivona C, Rockey M, Henry D, et al
    Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


    July 2015
  11. PELS E
    Comparison of saliva interleukin-2 concentration to the condition of gums in children with acute lymphoblastic leukaemia during anti-tumour treatment.
    Cancer Chemother Pharmacol. 2015;76:205-10.
    PubMed     Text format     Abstract available


    June 2015
  12. TEDESCHI PM, Kathari YK, Johnson-Farley N, Bertino JR, et al
    Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination.
    Cancer Chemother Pharmacol. 2015;75:1247-52.
    PubMed     Text format     Abstract available


    May 2015
  13. BRONDFIELD S, Umesh S, Corella A, Zuber J, et al
    Direct and indirect targeting of MYC to treat acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  14. VANG SI, Schmiegelow K, Frandsen T, Rosthoj S, et al
    Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Cancer Chemother Pharmacol. 2015;75:1089-93.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: